AU2006205220B2 - Heterocyclic carboxamide compounds as steroid nuclear receptors ligands - Google Patents

Heterocyclic carboxamide compounds as steroid nuclear receptors ligands Download PDF

Info

Publication number
AU2006205220B2
AU2006205220B2 AU2006205220A AU2006205220A AU2006205220B2 AU 2006205220 B2 AU2006205220 B2 AU 2006205220B2 AU 2006205220 A AU2006205220 A AU 2006205220A AU 2006205220 A AU2006205220 A AU 2006205220A AU 2006205220 B2 AU2006205220 B2 AU 2006205220B2
Authority
AU
Australia
Prior art keywords
optionally substituted
phenyl
pyrrole
carboxylic acid
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006205220A
Other languages
English (en)
Other versions
AU2006205220A1 (en
Inventor
Brenton Flatt
Xiao-Hui Gu
Richard Martin
Raju Mohan
Brett Murphy
Michael C. Nyman
William C. Stevens Jr.
Tie-Lin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2006205220A1 publication Critical patent/AU2006205220A1/en
Application granted granted Critical
Publication of AU2006205220B2 publication Critical patent/AU2006205220B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2006205220A 2005-01-10 2006-01-06 Heterocyclic carboxamide compounds as steroid nuclear receptors ligands Ceased AU2006205220B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64283905P 2005-01-10 2005-01-10
US60/642,839 2005-01-10
PCT/US2006/000319 WO2006076202A1 (en) 2005-01-10 2006-01-06 Heterocyclic carboxamide compounds as steroid nuclear receptors ligands

Publications (2)

Publication Number Publication Date
AU2006205220A1 AU2006205220A1 (en) 2006-07-20
AU2006205220B2 true AU2006205220B2 (en) 2012-09-13

Family

ID=36178222

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006205220A Ceased AU2006205220B2 (en) 2005-01-10 2006-01-06 Heterocyclic carboxamide compounds as steroid nuclear receptors ligands

Country Status (6)

Country Link
US (1) US20110144128A1 (https=)
EP (1) EP1844020B1 (https=)
JP (1) JP5123668B2 (https=)
AU (1) AU2006205220B2 (https=)
CA (1) CA2593156C (https=)
WO (1) WO2006076202A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937184B2 (en) * 2005-02-16 2015-01-20 Abbvie B.V. 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
JP2008530179A (ja) * 2005-02-16 2008-08-07 ソルベイ・フアーマシユーチカルズ・ベー・ブイ カンナビノイドｃｂ２受容体モジュレーターとしての１ｈ−イミダゾール誘導体
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
WO2007024744A2 (en) * 2005-08-21 2007-03-01 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
US8137963B2 (en) * 2006-08-24 2012-03-20 Hiroshima University Method for highly amplifying target gene in mammalian cell and vector therefor
DK2089367T3 (da) 2006-10-31 2012-02-06 Pfizer Prod Inc Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
EP2133330B1 (en) * 2007-04-09 2014-01-01 Daiichi Sankyo Company, Limited Atropisomer of pyrrole derivative
WO2009124037A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
US8410279B2 (en) * 2008-06-11 2013-04-02 Genentech, Inc. Substituted pyrroles and methods of use
WO2010098286A1 (ja) * 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
TWI532725B (zh) 2010-01-26 2016-05-11 賽諾菲阿凡提斯公司 經氧取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
US20140322242A1 (en) * 2010-11-24 2014-10-30 Icahn School Of Medicine At Mount Sinai Materials and methods for the prevention and treatment of cancer
TWI523844B (zh) 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
AR085013A1 (es) 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
CA2840516A1 (en) * 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
KR20140049020A (ko) 2011-07-26 2014-04-24 사노피 치환된 ３-（티아졸-４-카보닐）- 또는 ３-（티아졸-２-카보닐）아미노프로피온산 유도체 및 이의 약제로서의 용도
MY169319A (en) 2011-07-26 2019-03-21 Sanofi Sa 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
EP2765859B1 (en) * 2011-10-13 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US20130123325A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
BR112015002152B1 (pt) * 2012-08-02 2021-04-27 Nerviano Medical Sciences S.R.L. Compostos de pirróis substituídos ativos como inibidores de quinases, processo para a preparação de tais compostos, composição farmacêutica, método in vitro para a inibição da atividade de proteínas quinases da família jak e produto compreendendo os referidos compostos
AR094412A1 (es) 2013-01-10 2015-07-29 Gruenenthal Gmbh Carboxamidas basadas en pirazolilo i
KR20150103752A (ko) 2013-01-10 2015-09-11 그뤼넨탈 게엠베하 Crac 채널 억제제로서의 피라졸릴계 카복스아미드 ⅱ
SG11201506190QA (en) 2013-03-28 2015-09-29 Sanofi Sa Biaryl-propionic acid derivatives and their use as pharmaceuticals
TW201522318A (zh) 2013-03-28 2015-06-16 Sanofi Sa 聯芳基丙酸及其作為醫藥品之用途
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
WO2015197187A1 (en) 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides v
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
CN108822079B (zh) * 2018-05-31 2019-12-06 陈刚 一种酯类衍生物及其在防治心脑血管疾病中的应用
CN108840856B (zh) * 2018-05-31 2019-12-24 陈�峰 一种酯类衍生物及其在防治心脑血管疾病中的应用
JP7530889B2 (ja) 2018-10-05 2024-08-08 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン
EP3950674A4 (en) * 2019-10-25 2022-12-28 Sunshine Lake Pharma Co., Ltd. Pyrrole amide compound and use thereof
AU2022264993A1 (en) * 2021-04-26 2023-11-09 Sunshine Lake Pharma Co., Ltd. Preparation method for pyrrole amide compound
CN115784961B (zh) * 2021-09-10 2026-03-31 上海鼎雅药物化学科技有限公司 埃沙西林酮及其中间体的合成方法
CN113929591A (zh) * 2021-10-09 2022-01-14 中国科学技术大学 具有抗增殖活性的抑制剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029007A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
WO2002096882A1 (en) * 2001-05-31 2002-12-05 Nihon Nohyaku Co., Ltd. Substituted anilide derivatives, intermediates thereof, agricultural and horticultural chemicals, and their usage
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003027076A2 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
WO2003063781A2 (en) * 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2004189738A (ja) * 2002-11-29 2004-07-08 Nippon Nohyaku Co Ltd 置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2104931B1 (https=) * 1970-09-08 1975-01-10 Ferlux
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
AU2002338642A1 (en) * 2001-04-13 2002-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2004085419A1 (de) * 2003-03-24 2004-10-07 Basf Aktiengesellschaft Trifluormethyl-thiophencarbonsäureanilide und ihre verwendung als fungizide
EP1653949A4 (en) * 2003-08-07 2009-04-22 Merck & Co Inc PYRAZOL CARBOXAMIDE AS AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1
CA2573426C (en) * 2004-07-30 2015-11-17 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029007A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
WO2002096882A1 (en) * 2001-05-31 2002-12-05 Nihon Nohyaku Co., Ltd. Substituted anilide derivatives, intermediates thereof, agricultural and horticultural chemicals, and their usage
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003027076A2 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
WO2003063781A2 (en) * 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2004189738A (ja) * 2002-11-29 2004-07-08 Nippon Nohyaku Co Ltd 置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ANTOLINI, M. et al. Bioorganic & Medicinal Chemistry Letters (1999), 9, 1023-1028 *
CAPUANO, L. et al. Liebigs Ann. Chem. (1982), 12, 2178-2188 *
DYCK, B. et al. Bioorganic & Medicinal Chemistry Letters (2004), 14, 1151-1154 *
GOMPPER, R. et al. Chemische Berichte (1959), 92(3), 550-563 *
Krishnamurthy, M. et al (2004) Bioorg. Med. Chem., 12:393-404 *
KUDO, N. et al. Chem. Pharm. Bull. (1999), 47(6), 857-868 *
LAN, R. et al. J. Med. Chem. (1999), 42, 769-776 *
PAPADOPOULOS, E. P. Journal of Organic Chemistry (1977), 42 (24), 3925-3929 *
Parlow, J. J. et al (1997) J. Org. Chem., 62:5908-5919 *
SHIM, J-Y. et al. J. Med. Chem. (2002), 45, 1447-1459 *
UEDA, T. et al. Tetrahedron Letters (1988), 29 (36), 4607-4610 *

Also Published As

Publication number Publication date
CA2593156C (en) 2015-05-05
JP2008526869A (ja) 2008-07-24
JP5123668B2 (ja) 2013-01-23
CA2593156A1 (en) 2006-07-20
US20110144128A1 (en) 2011-06-16
EP1844020B1 (en) 2017-09-06
AU2006205220A1 (en) 2006-07-20
EP1844020A1 (en) 2007-10-17
WO2006076202A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
AU2006205220B2 (en) Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
AU2005266890C1 (en) Pyrrole derivatives as pharmaceutical agents
JP2008508308A5 (https=)
CN101679297B (zh) Lxr和fxr调节剂
JP5244589B2 (ja) イミダゾールに基づくｌｘｒモジュレーター
CN101006052B (zh) 作为药用制剂的吡咯衍生物
WO2007024744A2 (en) Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
CN101248049B (zh) 咪唑类lxr调节剂
HK1108878A (en) Pyrrole derivatives as pharmaceutical agents
HK1108878B (en) Pyrrole derivatives as pharmaceutical agents
MX2007001201A (en) Pyrrole derivatives as pharmaceutical agents
Khadse et al. Rational design and synthesis of benzamides as non-ulcerogenic anti-inflammatory agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired